Administration of an API in a dissolved form allows bypassing the dissolution step, thus accelerating the absorption phase.

Our formulation experts have proven track experience in selecting the best approaches to overcome the low aqueous solubility of new chemical entities e.g. modification of the API via salt formation, and incorporation of solubilising excipients such as complexing agents, surfactants or co-solvents.

Reducing drug particle size to micro- or even nanometer scale leads to a drastic increase in the surface area available for solvation and thus improved dissolution kinetics.

At Eurofins CDMO, we have extensive experience in top-down particle size reduction processes via wet milling followed by stabilisation of these nanosuspensions.

These formulations typically consist of lipids, surfactants, and co-solvents, which solubilise the drug and facilitate its absorption in the gastrointestinal tract.

Self-emulsifying drug delivery systems (SEDDS) are a prime example of lipid formulations designed to enhance drug solubility and bioavailability. Upon administration, SEDDS spontaneously form oil-in-water emulsions, increasing drug solubilisation and promoting absorption through lymphatic transport. 

ASDs represent an innovative approach for bioavailability enhancement by dispersing poorly water-soluble drugs in a polymer matrix. Unlike crystalline drug formulations, amorphous drugs exhibit higher energy states and greater molecular mobility, leading to enhanced dissolution rates and improved bioavailability. By preventing drug recrystallisation and maintaining a high-energy amorphous state, ASDs enhance drug solubility, dissolution kinetics, and absorption.

At Eurofins CDMO, we have in-house expertise to produce ASDs via spray-drying and bead-coating technologies.